KALA BIO INC (KALA) Stock Fundamental Analysis

NASDAQ:KALA • US4831192020

0.404 USD
-0.01 (-1.51%)
At close: Feb 25, 2026
0.4 USD
0 (-0.99%)
After Hours: 2/25/2026, 8:25:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

KALA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. KALA may be in some trouble as it scores bad on both profitability and health. KALA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year KALA has reported negative net income.
  • In the past year KALA has reported a negative cash flow from operations.
  • KALA had negative earnings in each of the past 5 years.
  • In the past 5 years KALA always reported negative operating cash flow.
KALA Yearly Net Income VS EBIT VS OCF VS FCFKALA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

  • KALA has a worse Return On Assets (-74.28%) than 64.30% of its industry peers.
  • KALA's Return On Equity of -627.91% is on the low side compared to the rest of the industry. KALA is outperformed by 77.16% of its industry peers.
Industry RankSector Rank
ROA -74.28%
ROE -627.91%
ROIC N/A
ROA(3y)-65.78%
ROA(5y)-69.35%
ROE(3y)-371.5%
ROE(5y)-413.54%
ROIC(3y)N/A
ROIC(5y)N/A
KALA Yearly ROA, ROE, ROICKALA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

  • KALA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KALA Yearly Profit, Operating, Gross MarginsKALA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, KALA has more shares outstanding
  • Compared to 5 years ago, KALA has more shares outstanding
  • The debt/assets ratio for KALA has been reduced compared to a year ago.
KALA Yearly Shares OutstandingKALA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
KALA Yearly Total Debt VS Total AssetsKALA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • KALA has an Altman-Z score of -21.44. This is a bad value and indicates that KALA is not financially healthy and even has some risk of bankruptcy.
  • KALA's Altman-Z score of -21.44 is on the low side compared to the rest of the industry. KALA is outperformed by 84.07% of its industry peers.
  • A Debt/Equity ratio of 2.65 is on the high side and indicates that KALA has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 2.65, KALA is doing worse than 79.08% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2.65
Debt/FCF N/A
Altman-Z -21.44
ROIC/WACCN/A
WACCN/A
KALA Yearly LT Debt VS Equity VS FCFKALA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

  • A Current Ratio of 1.99 indicates that KALA should not have too much problems paying its short term obligations.
  • The Current ratio of KALA (1.99) is worse than 76.39% of its industry peers.
  • A Quick Ratio of 1.99 indicates that KALA should not have too much problems paying its short term obligations.
  • KALA has a worse Quick ratio (1.99) than 74.66% of its industry peers.
Industry RankSector Rank
Current Ratio 1.99
Quick Ratio 1.99
KALA Yearly Current Assets VS Current LiabilitesKALA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 54.09% over the past year.
EPS 1Y (TTM)54.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • KALA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.21% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y49.59%
EPS Next 2Y38.5%
EPS Next 3Y25.21%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KALA Yearly Revenue VS EstimatesKALA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2019 2020 2021 2022 2031 2032 50M 100M 150M
KALA Yearly EPS VS EstimatesKALA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -50 -100

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for KALA. In the last year negative earnings were reported.
  • Also next year KALA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KALA Price Earnings VS Forward Price EarningsKALA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KALA Per share dataKALA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4 -5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as KALA's earnings are expected to grow with 25.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.5%
EPS Next 3Y25.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • KALA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KALA BIO INC

NASDAQ:KALA (2/25/2026, 8:25:00 PM)

After market: 0.4 0 (-0.99%)

0.404

-0.01 (-1.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-19
Earnings (Next)03-30
Inst Owners37.02%
Inst Owner Change34.52%
Ins Owners2%
Ins Owner Change-6.25%
Market Cap11.25M
Revenue(TTM)N/A
Net Income(TTM)-35.84M
Analysts45.71
Price Target1.53 (278.71%)
Short Float %2.09%
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.62%
Min EPS beat(2)1.58%
Max EPS beat(2)41.67%
EPS beat(4)4
Avg EPS beat(4)25.08%
Min EPS beat(4)1.58%
Max EPS beat(4)41.67%
EPS beat(8)7
Avg EPS beat(8)15.48%
EPS beat(12)7
Avg EPS beat(12)-2.76%
EPS beat(16)9
Avg EPS beat(16)-6.88%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.97
P/tB 1.97
EV/EBITDA N/A
EPS(TTM)-5.72
EYN/A
EPS(NY)-0.9
Fwd EYN/A
FCF(TTM)-1.15
FCFYN/A
OCF(TTM)-1.15
OCFYN/A
SpS0
BVpS0.2
TBVpS0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -74.28%
ROE -627.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.78%
ROA(5y)-69.35%
ROE(3y)-371.5%
ROE(5y)-413.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 2.65
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.3%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.99
Quick Ratio 1.99
Altman-Z -21.44
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)113.01%
Cap/Depr(5y)128.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.44%
EPS Next Y49.59%
EPS Next 2Y38.5%
EPS Next 3Y25.21%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.7%
OCF growth 3YN/A
OCF growth 5YN/A

KALA BIO INC / KALA FAQ

What is the fundamental rating for KALA stock?

ChartMill assigns a fundamental rating of 1 / 10 to KALA.


What is the valuation status of KALA BIO INC (KALA) stock?

ChartMill assigns a valuation rating of 1 / 10 to KALA BIO INC (KALA). This can be considered as Overvalued.


How profitable is KALA BIO INC (KALA) stock?

KALA BIO INC (KALA) has a profitability rating of 0 / 10.


How financially healthy is KALA BIO INC?

The financial health rating of KALA BIO INC (KALA) is 1 / 10.